Dr. Craig Koniver - The Godfather of Peptides | SRS #330

Guest appearances — Dr. Craig Koniver, MD — Dr. Craig Koniver - The Godfather of Peptides | SRS #330

Channel: Podcast Summaries · Our label: Guest appearance — Dr. Craig Koniver, MD as guest on host channels. The host channel is named on every page. · Source: youtube.com/watch?v=KuYrAvXiDis

Guest appearance: Dr. Craig Koniver, MD appears as a guest on Podcast Summaries. This page is filed under the host channel and tagged as a guest appearance in our library.

What this video covers

Craig Conover shares his extensive experience in biological optimization and longevity, diving deep into peptides, mitochondrial health, hormone replacement, and cutting-edge therapies. Conover recounts a life-changing health crisis at age 46 when he was diagnosed with a portal vein thrombosis and a suspicious mass on his pancreas. What seemed like a near-fatal setback turned into a miraculous healing that profoundly transformed his perspective on medicine and life. His experience reinforced a holistic view of health, blending spirituality with science.

Summary drawn from this video’s own transcript (banked in our research library, pulled 2026-11-07). Claims below are the speaker’s — attributed, not endorsed. This site publishes no dosing, protocol, or sourcing information.

Key points, in the speaker’s own framing

• Craig Conover shares his extensive experience in biological optimization and longevity, diving deep into peptides, mitochondrial health, hormone replacement, and cutting-edge therapies.
• Hormonal optimization is addressed as a tangible and powerful factor in health, particularly testosterone for men and thyroid function for women.
• Defined as small chains of amino acids that signal and whisper to cells rather than blunt force sledgehammer pharmaceuticals, peptides offer a safe, customizable way to promote repair, recovery, and regeneration.
• Conover discusses concerns around regulatory oversight, specifically the FDA’s attempts to restrict compounding pharmacies from producing peptides due to their lack of formal FDA approval.
• Though clinical safety with peptides appears strong, regulatory fears linger, and formal long-term studies are lacking.
• Conover advocates for a more nuanced regulatory paradigm that better accommodates compounds with demonstrated safety and clinical benefit.

Read next

• BPC-157 — compound page
• TB-500 — compound page
• SS-31 — more videos
• NAD+ — more videos
• All videos from this channel

Educational information only — not medical advice. Peptides discussed on this page include substances that are not FDA-approved.